Quick Answer
Orchestra BioMed Holdings, Inc. reported Net Income Loss of -$52.70 million for the year ending 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +13.6% in Net Income Loss from 2024 to 2025.
- This data is from Orchestra BioMed Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$15.2 thousand | Q3 2020: -$66.2 thousand | Q1 2021: -$108.0 thousand | Q2 2021: -$92.3 thousand | Q3 2021: -$90.4 thousand | Q1 2022: -$5.73 million | Q2 2022: -$7.85 million | Q3 2022: -$10.28 million | Q1 2023: -$10.94 million | Q2 2023: -$12.05 million | Q3 2023: -$13.32 million | Q1 2024: -$13.46 million | Q2 2024: -$15.98 million | Q3 2024: -$15.43 million | Q1 2025: -$18.76 million | Q2 2025: -$19.36 million | Q3 2025: -$20.83 million.
- Over the full 5 years of available data (2021 to 2025), Orchestra BioMed Holdings, Inc.'s Net Income Loss has declined by 13,814.3%.
- Historical annual values: Fiscal year 2025: -$52.70 million | Fiscal year 2024: -$61.02 million | Fiscal year 2023: -$49.12 million | Fiscal year 2022: -$33.61 million | Fiscal year 2021: -$378.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: